| Model‐based drug development RL Lalonde, KG Kowalski, MM Hutmacher, W Ewy, DJ Nichols, ... Clinical Pharmacology & Therapeutics 82 (1), 21-32, 2007 | 567 | 2007 |
| Clinical pharmacokinetics of pregabalin in healthy volunteers HN Bockbrader, LL Radulovic, EL Posvar, JC Strand, CW Alvey, JA Busch, ... The Journal of Clinical Pharmacology 50 (8), 941-950, 2010 | 250 | 2010 |
| Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID‐19 B Damle, M Vourvahis, E Wang, J Leaney, B Corrigan Clinical Pharmacology & Therapeutics 108 (2), 201-211, 2020 | 238 | 2020 |
| Disease progression meta-analysis model in Alzheimer's disease K Ito, S Ahadieh, B Corrigan, J French, T Fullerton, T Tensfeldt, ... Alzheimer's & Dementia 6 (1), 39-53, 2010 | 204 | 2010 |
| How modeling and simulation have enhanced decision making in new drug development R Miller, W Ewy, BW Corrigan, D Ouellet, D Hermann, KG Kowalski, ... Journal of pharmacokinetics and pharmacodynamics 32 (2), 185-197, 2005 | 188 | 2005 |
| Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database K Ito, B Corrigan, Q Zhao, J French, R Miller, H Soares, E Katz, T Nicholas, ... Alzheimer's & Dementia 7 (2), 151-160, 2011 | 172 | 2011 |
| Exposure‐response analysis of pregabalin add‐on treatment of patients with refractory partial seizures R Miller, B Frame, B Corrigan, P Burger, H Bockbrader, E Garofalo, ... Clinical Pharmacology & Therapeutics 73 (6), 491-505, 2003 | 110 | 2003 |
| Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis JA Rogers, D Polhamus, WR Gillespie, K Ito, K Romero, R Qiu, ... Journal of pharmacokinetics and pharmacodynamics 39 (5), 479-498, 2012 | 106 | 2012 |
| Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling S Ueckert, EL Plan, K Ito, MO Karlsson, B Corrigan, AC Hooker, ... Pharmaceutical research 31 (8), 2152, 2014 | 102 | 2014 |
| The future is now: model‐based clinical trial design for Alzheimer's disease K Romero, K Ito, JA Rogers, D Polhamus, R Qiu, D Stephenson, R Mohs, ... Clinical Pharmacology & Therapeutics 97 (3), 210-214, 2015 | 88 | 2015 |
| Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID‐19, in subjects with renal impairment SS Toussi, JM Neutel, J Navarro, RA Preston, H Shi, O Kavetska, ... Clinical Pharmacology & Therapeutics 112 (4), 892-900, 2022 | 70 | 2022 |
| Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database K Ito, B Corrigan, K Romero, R Anziano, J Neville, D Stephenson, ... Journal of Alzheimer’s Disease 37 (1), 173-183, 2013 | 62 | 2013 |
| Metabolic disposition of pregabalin in healthy volunteers C BW Clin Pharmacol Ther 69, 18, 2001 | 61 | 2001 |
| The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats M Vakily, B Corrigan, F Jamali Pharmaceutical research 12 (11), 1652-1657, 1995 | 59 | 1995 |
| Alzheimer’s Disease Working Group (2010) Disease progression meta-analysis model in Alzheimer’s disease K Ito, S Ahadieh, B Corrigan, J French, T Fullerton, T Tensfeldt Alzheimers Dement 6, 39-53, 0 | 59 | |
| Demographic diversity of participants in Pfizer sponsored clinical trials in the United States M Rottas, P Thadeio, R Simons, R Houck, D Gruben, D Keller, ... Contemporary Clinical Trials 106, 106421, 2021 | 54 | 2021 |
| Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures HN Bockbrader, P Burger, L Knapp, BW Corrigan Epilepsia 52 (2), 248-257, 2011 | 49 | 2011 |
| Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson's disease clinical trials: a disease progression modeling analysis DJ Conrado, T Nicholas, K Tsai, S Macha, V Sinha, J Stone, B Corrigan, ... Clinical and Translational Science 11 (1), 63-70, 2018 | 47 | 2018 |
| Quantitative prediction of renal transporter-mediated clinical drug–drug interactions B Feng, S Hurst, Y Lu, MV Varma, CJ Rotter, A El-Kattan, P Lockwood, ... Molecular Pharmaceutics 10 (11), 4207-4215, 2013 | 45 | 2013 |
| Role of disease progression models in drug development JS Barrett, T Nicholas, K Azer, BW Corrigan Pharmaceutical Research 39 (8), 1803-1815, 2022 | 36 | 2022 |
James Anthony RogersMetrum Research GroupVerified email at metrumrg.com
